文献速递淋巴瘤

新诊断弥漫性大B细胞淋巴瘤中由中期PET驱动的策略:我们是否该信任这个驱动因素?

Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?
PubMed 文献 · Blood · 2017-04-17

本文综述了弥漫性大B细胞淋巴瘤(DLBCL)中期PET(iPET)相关研究,涵盖分析方法、时机及iPET驱动治疗的研究。iPET在2和/或4疗程免疫化疗后阴性预测价值很好,视觉法适用于局限期,半定量法如ΔSUVmax适用于晚期。迄今无试验证明iPET驱动策略优于标准策略,但其预测价值支持日常用于治疗决策。

要点

  • iPET在2和/或4疗程免疫化疗后阴性预测价值很好,视觉法和半定量法均可。
  • 视觉法可准确预测局限期患者结局;半定量法如ΔSUVmax适用于晚期DLBCL。
  • 低ΔSUVmax有助于识别复发风险平均50%的患者,需审查其预定治疗。

核心结论

  • 迄今无试验证明iPET驱动策略在DLBCL中具有优越性。
  • iPET的阴性预测价值和阳性预测价值良好,支持其作为日常实践中比增强CT更好的预测工具用于治疗决策。

研究设计与样本

  • 本文为视角综述,回顾了已发表的DLBCL中iPET研究,包括iPET分析方法、时机及iPET驱动治疗的研究。

主要发现

  • iPET在2和/或4疗程免疫化疗后实施时,采用视觉(定性)和半定量方法均具有很好的阴性预测价值。
  • 视觉法可准确预测局限期疾病患者的结局。
  • 半定量方法如最大标准化摄取值差值变化(ΔSUVmax)适用于晚期DLBCL患者,iPET可识别继续标准治疗结局很好的患者。
  • 低ΔSUVmax有助于识别复发风险平均为50%的患者,并需审查其预定治疗。

关键数值与推荐

  • iPET在2和/或4疗程免疫化疗后实施,采用视觉和半定量方法,阴性预测价值很好。
  • 视觉法准确预测局限期疾病患者结局;半定量法如ΔSUVmax适用于晚期DLBCL。
  • 低ΔSUVmax识别复发风险平均50%的患者。

临床怎么用

  • iPET的阴性预测价值和阳性预测价值良好,支持其作为日常实践中比增强CT更好的预测工具用于治疗决策。

局限性

  • 迄今无试验证明iPET驱动策略在DLBCL中具有优越性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET) has become a central tool for both accurate initial staging and determination of prognosis after treatment of diffuse large B-cell lymphoma (DLBCL). However, the role of PET during treatment (iPET) in daily practice remains a matter of significant debate. This perspective reviews the published studies on iPET in DLBCL, including the methods used to analyze iPET, its timing, and studies of iPET-driven therapy to illuminate where daily practice may benefit from the use of iPET. When performed after 2 and/or 4 courses of immunochemotherapy, iPET has a very good negative predictive value, utilizing both visual (qualitative) and semiquantitative methods. The visual method accurately predicts outcome for patients with limited disease. The semiquantitative method, eg, the change of the difference of maximum standardized uptake value (ΔSUVmax), is for patients with advanced DLBCL, for whom iPET identifies patients with very good outcome with continuation of standard therapy. A low ΔSUVmax also helps identify patients with a risk for relapse averaging 50% and warrants review of their scheduled therapy. To date, no trial has demonstrated the superiority of an iPET-driven strategy in DLBCL. However, the very good negative and good positive predictive values of iPET support its use in daily practice as a better predictive tool than contrast-enhanced computed tomographic scan for therapeutic decision making.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Le Gouill S, Casasnovas RO. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver? Blood. 2017. PMID: 28416502. doi:10.1182/blood-2016-05-672196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。